Market cap
$1,149 Mln
Recently Viewed
Clear All$13.59
$-0.19
(-1.34%)
As on 27-Apr-2026 16:15EDT
Market cap
$1,149 Mln
Revenue (TTM)
$31 Mln
P/E Ratio
--
P/B Ratio
3.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
11.6
Debt to Equity
0.1
Book Value
$4.2
EPS
$-3.2
Face value
--
Shares outstanding
83,431,950
CFO
$-243.45 Mln
EBITDA
$-349.74 Mln
Net Profit
$-475.05 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eyepoint Pharmaceuticals Inc (EYPT)
| -25.6 | 4.0 | -12.1 | 113.3 | 21.0 | 5.7 | -7.7 |
|
BSE Sensex*
| -9.2 | 4.5 | -6.1 | -2.9 | 8.2 | 9.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Eyepoint Pharmaceuticals Inc (EYPT)
| 145.2 | -67.5 | 560.3 | -71.4 | 86.0 | -57.5 | -18.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eyepoint Pharmaceuticals Inc (EYPT)
|
13.6 | 1,148.9 | 31.4 | -232.0 | -544.4 | -72.2 | -- | 3.8 |
| 12.6 | 3,993.9 | 2,323.3 | 44.1 | 12.3 | -- | 56.9 | 105.4 | |
| 41.0 | 5,233.8 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.4 | 14.1 | |
| 187.4 | 9,512.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 107.7 | |
| 74.5 | 14,206.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 46.2 | 4,944.9 | 761.4 | 99.7 | 7.3 | 15 | 56.2 | 7.6 | |
| 14.0 | 11,337.9 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.6 | 2.8 | |
| 22.1 | 11,181.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.7 | |
| 8.1 | 5,499.1 | 7,682.7 | 438.7 | 15.9 | 7.5 | 11.7 | 1.1 | |
| 241.8 | 4,634.3 | 268.1 | 124.5 | 60.0 | 13.5 | 37.7 | 4.6 |
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug... delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts. Read more
President, CEO & Director
Dr. Jay S. Duker M.D.
President, CEO & Director
Dr. Jay S. Duker M.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Eyepoint Pharmaceuticals Inc (EYPT) is $13.59 (NASDAQ) as of 27-Apr-2026 16:15 EDT. Eyepoint Pharmaceuticals Inc (EYPT) has given a return of 21.02% in the last 3 years.
Since, TTM earnings of Eyepoint Pharmaceuticals Inc (EYPT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.75
|
4.36
|
|
2024
|
-3.19
|
1.24
|
|
2023
|
-12.73
|
3.38
|
|
2022
|
-1.27
|
1.34
|
|
2021
|
-6.08
|
1.93
|
The 52-week high and low of Eyepoint Pharmaceuticals Inc (EYPT) are Rs 19.11 and Rs 5.30 as of 28-Apr-2026.
Eyepoint Pharmaceuticals Inc (EYPT) has a market capitalisation of $ 1,149 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Eyepoint Pharmaceuticals Inc (EYPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.